Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR–TKIs) are widely used as the first‐line systemic treatment for patients with unresectable advanced or metastatic EGFR‐mutated non‐small cell lung carcinoma (NSCLC).1, 2. Here, EGFR is linked to non-small cell lung carcinoma.